Methylation-sensitive restriction endonuclease-based amplification assay for detecting DNA methylation in colorectal cancer: a cross-sectional study

Abstract Background This study evaluates the clinical utility of combined SDC2 and ADHFE1 methylation analysis for colorectal cancer (CRC) detection using a methylation-sensitive restriction endonuclease (MSRE)-based assay. Methods Leveraging the specificity of MSRE, we developed a streamlined amplification assay that directly analyzes methylation status of SDC2 and ADHFE1 after mixing nucleic acids with PCR reagent. A cohort of 274 participants was stratified into six groups: CRC ( n = 117), advanced adenoma (AA, n = 22), polyps ( n = 30), intestinal disease control (IDC, n = 39), other gastrointestinal disease control (OGDC, n = 24), and healthy controls (HC, n = 42). SDC2 and ADHFE1 methylation levels in fecal samples were assessed, and diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. Results The CRC group exhibited significantly higher SDC2 and ADHFE1 methylation positivity rates compared to all comparator groups, including AA, polyps, IDC, OGDC, and HC ( P < 0.01). No significant differences were observed in the methylation positivity rates of SDC2, ADHFE1 or their combination across different TNM stages and levels of tumor differentiation. Joint SDC2 and ADHFE1 analysis increased sensitivity for CRC detection to 82.9% (vs. 64.1% and 65.0% for ADHFE1 and SDC2) with an AUC of 0.865 (95% CI: 0.817–0.913). For early-stage CRC (stages I + II), the dual-gene panel achieved an AUC of 0.872. However, the ability to discriminate between AA and HC (AUC: 0.693) or IDC (AUC: 0.615) remained limited in our dual-gene assay. Conclusions The combined SDC2/ADHFE1 MSRE-based assay significantly improves diagnostic sensitivity for CRC, demonstrating superior differentiation of CRC from benign intestinal pathologies and precancerous lesions (AA and polyps). This non-invasive approach shows promise as a supplementary tool for CRC screening.

Authors

Institutions

Publication Details

Journal
BMC Gastroenterology
Published
2026-08-03
DOI
https://doi.org/10.1186/s12876-026-05034-7
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Methylation-sensitive restriction endonuclease-based amplification assay for detecting DNA methylation in colorectal cancer: a cross-sectional study

Meifang He, Zhikang Li, Jiali Wu, Shayuanzi Huang et al.
BMC Gastroenterology
Epigenetics and DNA Methylation
article

Methylation-sensitive restriction endonuclease-based amplification assay for detecting DNA methylation in colorectal cancer: a cross-sectional study

Meifang He, Zhikang Li, Jiali Wu, Shayuanzi Huang, Anzhi Huang, Dong Wang, Guoshan He, Ruizhi Wang, Lu Ai, Ruizhao Zhang
article en

Abstract

Abstract Background This study evaluates the clinical utility of combined SDC2 and ADHFE1 methylation analysis for colorectal cancer (CRC) detection using a methylation-sensitive restriction endonuclease (MSRE)-based assay. Methods Leveraging the specificity of MSRE, we developed a streamlined amplification assay that directly analyzes methylation status of SDC2 and ADHFE1 after mixing nucleic acids with PCR reagent. A cohort of 274 participants was stratified into six groups: CRC ( n = 117), advanced adenoma (AA, n = 22), polyps ( n = 30), intestinal disease control (IDC, n = 39), other gastrointestinal disease control (OGDC, n = 24), and healthy controls (HC, n = 42). SDC2 and ADHFE1 methylation levels in fecal samples were assessed, and diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. Results The CRC group exhibited significantly higher SDC2 and ADHFE1 methylation positivity rates compared to all comparator groups, including AA, polyps, IDC, OGDC, and HC ( P < 0.01). No significant differences were observed in the methylation positivity rates of SDC2, ADHFE1 or their combination across different TNM stages and levels of tumor differentiation. Joint SDC2 and ADHFE1 analysis increased sensitivity for CRC detection to 82.9% (vs. 64.1% and 65.0% for ADHFE1 and SDC2) with an AUC of 0.865 (95% CI: 0.817–0.913). For early-stage CRC (stages I + II), the dual-gene panel achieved an AUC of 0.872. However, the ability to discriminate between AA and HC (AUC: 0.693) or IDC (AUC: 0.615) remained limited in our dual-gene assay. Conclusions The combined SDC2/ADHFE1 MSRE-based assay significantly improves diagnostic sensitivity for CRC, demonstrating superior differentiation of CRC from benign intestinal pathologies and precancerous lesions (AA and polyps). This non-invasive approach shows promise as a supplementary tool for CRC screening.

BMC Gastroenterology
Sun Yat-sen University (CN), First Affiliated Hospital of GuangXi Medical University (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), Guangzhou Quality Supervision, Inspection and Research Institute (CN), Guangdong Academy of Medical Sciences (CN), Guangdong Provincial Center for Disease Control and Prevention (CN), Guangdong Provincial People's Hospital (CN)
National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Basic and Applied Basic Research Foundation of Guangdong Province
Reduced inequalities
Openalex Percentile: Top 16%
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.